Tag: Novo Holdings acquisition of Catalent

news-21102024-151856

Catalent’s Deal with Novo Holdings: Customer Reassurance and Updates

Catalent, a major contract drug manufacturer, recently reassured its customers through an open letter that its proposed acquisition by Novo Nordisk’s parent company for $16.5 billion would not impact its ability to provide services...
news-18102024-025712

Opposition Mounts Against Catalent Sale to Novo Holdings: Consumer and Labor Groups Call on...

A group of organizations, including labor unions and consumer advocates, is calling on the Federal Trade Commission to block the acquisition of Catalent, a major contract drug manufacturer, by Novo Nordisk’s parent foundation for...